[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pkp2-arvc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pkp2-arvc":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100591144","a-study-to-assess-real-world-patient-characteristics-and-clinical-course-for-symptomatic-patients-with-pkp2-acm-100591144",false,"NCT06976606","A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM","An Observational Study to Assess Real-world Patient Characteristics, Clinical Course, and Treatment Patterns for Symptomatic Patients With Arrhythmogenic Cardiomyopathy (ACM) Due To a PlaKoPhilin-2 Pathogenic Variant (PKP2)","SNAPSHOT- PKP2","Inclusion Criteria:\n\n* Adults with a clinical diagnosis of ACM as defined by the 2010 revised Task Force Criteria (TFC)\n* Documentation of a pathogenic or likely pathogenic truncating variant in PKP2\n* Frequent premature ventricular contractions (PVCs)\n* Patients must have an ICD placed prior to enrollment\n* Left ventricular ejection fraction (LVEF) ≥ 50% for Part A participants. Left ventricular ejection fraction (LVEF) ≥40% for Part B participants.\n\nExclusion Criteria:\n\n* Evidence of variant(s) in addition to PKP2 that meet standard criteria to be considered pathogenic or likely pathogenic for an arrhythmogenic cardiomyopathy.\n* A history of other cardiac abnormalities as specified in the protocol.\n* New York Heart Association symptoms of heart failure of Class IV at the time of consent.\n* A history of prior gene transfer therapy.","ALL","18 Years","65 Years",{"count":21,"type":22},40,"ESTIMATED","1 Year","OBSERVATIONAL","An observational study to assess real-world patient characteristics and clinical course of disease in participants with PKP2-ACM.",[27,28,29],"Arrhythmogenic Cardiomyopathy","PKP2-ACM","PKP2-ARVC",[27,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"ACM","Cardiomyopathy","ARVC","Arrhythmogenic Right Ventricular","Arrhythmogenic Right Ventricular Dysplasia","Genetic cardiomyopathy","Gene Therapy","PKP2 Gene","Plakophilin-2","LX2020","SNAPSHOT-PKP2","Ventricular Arrhythmia","PVCs","Sudden Cardiac Death","Cardiac Arrest","RECRUITING","2025-05-13",{"date":49,"type":50},"2025-05-16","ACTUAL",{"date":52,"type":50},"2024-01-23",{"date":54,"type":22},"2027-09",{"name":56,"class":57},"Lexeo Therapeutics","INDUSTRY",6]